000299476 001__ 299476
000299476 005__ 20250515135516.0
000299476 0247_ $$2doi$$a10.1002/ijc.35363
000299476 0247_ $$2pmid$$apmid:39992017
000299476 0247_ $$2ISSN$$a0020-7136
000299476 0247_ $$2ISSN$$a1097-0215
000299476 037__ $$aDKFZ-2025-00436
000299476 041__ $$aEnglish
000299476 082__ $$a610
000299476 1001_ $$00009-0000-2897-3726$$aHaug, Ala Jabri$$b0
000299476 245__ $$aNon-steroidal anti-inflammatory medication use and endometrial cancer survival: A population-based Norwegian cohort study.
000299476 260__ $$aBognor Regis$$bWiley-Liss$$c2025
000299476 3367_ $$2DRIVER$$aarticle
000299476 3367_ $$2DataCite$$aOutput Types/Journal article
000299476 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747310053_1545
000299476 3367_ $$2BibTeX$$aARTICLE
000299476 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000299476 3367_ $$00$$2EndNote$$aJournal Article
000299476 500__ $$aVolume157, Issue2, 15 July 2025, Pages 277-287
000299476 520__ $$aWhile nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to improve survival in certain cancers, data in patients with endometrial cancer (EC) is conflicting. This study investigated use of aspirin and nonaspirin NSAIDs (NA-NSAIDs) and EC-specific-and all-cause death. This nationwide cohort study linked data from the Cancer Registry of Norway with The Norwegian Prescription database. Patients diagnosed with EC from 2004 to 2018 were included. Post-diagnosis exposure to aspirin and NA-NSAIDs was defined as ≥3 consecutive prescriptions ≥30 days after EC diagnosis, with pre-diagnosis use as ≥2 filled prescriptions <6 months prior to diagnosis. Follow-up started 10 months after diagnosis. Hazard ratios for the risk of death were calculated with multivariable Cox-regression models. Our study population included 7751 individuals with EC, 685 (9%) were aspirin users and 620 (8%) were NA-NSAIDs users. The median follow-up time was 5.0 years, with 1518 (20%) deaths observed (n = 728 (9%) EC-specific). In multivariable analysis, aspirin use was significantly associated with a 19% higher risk of all-cause death compared to non-users (HR = 1.19, 95% CI [1.01-1.41]). The association was stronger among combined pre- and postdiagnosis use (HR = 1.35 [1.12-1.64]). NA-NSAIDs use increased risk of cancer-related death (HR = 1.25 [0.99-1.58]) and there was a dose-response association with significantly higher risk of cancer-specific death with higher cumulative doses (HR = 1.33 [1.02-1.75]). We found a higher risk of cancer-specific-and all-cause death among patients that used aspirin and NA-NSAIDs after a diagnosis of EC. Further studies on the biological mechanisms underlying these associations are needed.
000299476 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000299476 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000299476 650_7 $$2Other$$aNSAIDS
000299476 650_7 $$2Other$$aaspirin
000299476 650_7 $$2Other$$aendometrial cancer
000299476 650_7 $$2Other$$asurvival
000299476 650_7 $$2Other$$atertiary prevention
000299476 7001_ $$aStøer, Nathalie$$b1
000299476 7001_ $$aLangseth, Hilde$$b2
000299476 7001_ $$aSiafarikas, Franziska$$b3
000299476 7001_ $$aBotteri, Edoardo$$b4
000299476 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée Turzanski$$b5$$udkfz
000299476 7001_ $$aLindemann, Kristina$$b6
000299476 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.35363$$gp. ijc.35363$$n2$$p277-287$$tInternational journal of cancer$$v157$$x0020-7136$$y2025
000299476 909CO $$ooai:inrepo02.dkfz.de:299476$$pVDB
000299476 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000299476 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000299476 9141_ $$y2025
000299476 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-17$$wger
000299476 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-17$$wger
000299476 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2024-12-17
000299476 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2024-12-17
000299476 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lEpidemiologie von Krebs$$x0
000299476 980__ $$ajournal
000299476 980__ $$aVDB
000299476 980__ $$aI:(DE-He78)C020-20160331
000299476 980__ $$aUNRESTRICTED